These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 33536086)

  • 1. Potential therapeutic targets shared between leishmaniasis and cancer.
    Rashidi S; Fernández-Rubio C; Manzano-Román R; Mansouri R; Shafiei R; Ali-Hassanzadeh M; Barazesh A; Karimazar M; Hatam G; Nguewa P
    Parasitology; 2021 May; 148(6):655-671. PubMed ID: 33536086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chitin binding protein as a possible RNA binding protein in Leishmania parasites.
    Rashidi S; Kalantar K; Fernandez-Rubio C; Anvari E; Nguewa P; Hatam G
    Pathog Dis; 2020 Feb; 78(1):. PubMed ID: 32053190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular targets and pathways for the treatment of visceral leishmaniasis.
    Jain V; Jain K
    Drug Discov Today; 2018 Jan; 23(1):161-170. PubMed ID: 28919438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topoisomerase 1B as a target against leishmaniasis.
    D'Annessa I; Castelli S; Desideri A
    Mini Rev Med Chem; 2015; 15(3):203-10. PubMed ID: 25769969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leishmaniasis and various immunotherapeutic approaches.
    Taslimi Y; Zahedifard F; Rafati S
    Parasitology; 2018 Apr; 145(4):497-507. PubMed ID: 27974063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a RAC/AKT-like gene in Leishmania parasites as a putative therapeutic target in leishmaniasis.
    Varela-M RE; Ochoa R; Muskus CE; Muro A; Mollinedo F
    Parasit Vectors; 2017 Oct; 10(1):458. PubMed ID: 29017516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic potential of immune cross-talk in leishmaniasis.
    Hartley MA; Kohl K; Ronet C; Fasel N
    Clin Microbiol Infect; 2013 Feb; 19(2):119-30. PubMed ID: 23398405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Network-Based Approaches Reveal Potential Therapeutic Targets for Host-Directed Antileishmanial Therapy Driving Drug Repurposing.
    Martinez-Hernandez JE; Hammoud Z; de Sousa AM; Kramer F; Monte-Neto RLD; Maracaja-Coutinho V; Martin AJM
    Microbiol Spectr; 2021 Oct; 9(2):e0101821. PubMed ID: 34668739
    [No Abstract]   [Full Text] [Related]  

  • 9. Mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets in the antileishmanial and anticancer activities of ether lipid edelfosine.
    Villa-Pulgarín JA; Gajate C; Botet J; Jimenez A; Justies N; Varela-M RE; Cuesta-Marbán Á; Müller I; Modolell M; Revuelta JL; Mollinedo F
    PLoS Negl Trop Dis; 2017 Aug; 11(8):e0005805. PubMed ID: 28829771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulation by chemotherapeutic agents against Leishmaniasis.
    Saha P; Mukhopadhyay D; Chatterjee M
    Int Immunopharmacol; 2011 Nov; 11(11):1668-79. PubMed ID: 21875692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leishmaniasis: clinical syndromes and treatment.
    McGwire BS; Satoskar AR
    QJM; 2014 Jan; 107(1):7-14. PubMed ID: 23744570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of heparan sulfate in host macrophage infection by
    Maciej-Hulme ML; Skidmore MA; Price HP
    Biochem Soc Trans; 2018 Aug; 46(4):789-796. PubMed ID: 29934302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The LABCG2 Transporter from the Protozoan Parasite Leishmania Is Involved in Antimony Resistance.
    Perea A; Manzano JI; Castanys S; Gamarro F
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3489-96. PubMed ID: 27021316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomics advances in the study of Leishmania parasites and leishmaniasis.
    de Jesus JB; Mesquita-Rodrigues C; Cuervo P
    Subcell Biochem; 2014; 74():323-49. PubMed ID: 24264252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protease inhibitors in potential drug development for Leishmaniasis.
    Das P; Alam MN; Paik D; Karmakar K; De T; Chakraborti T
    Indian J Biochem Biophys; 2013 Oct; 50(5):363-76. PubMed ID: 24772958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of dendritic cell function by Leishmania parasites.
    Soong L
    J Immunol; 2008 Apr; 180(7):4355-60. PubMed ID: 18354154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug search for leishmaniasis: a virtual screening approach by grid computing.
    Ochoa R; Watowich SJ; Flórez A; Mesa CV; Robledo SM; Muskus C
    J Comput Aided Mol Des; 2016 Jul; 30(7):541-52. PubMed ID: 27438595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of leishmaniasis: a review and assessment of recent research.
    Elmahallawy EK; Agil A
    Curr Pharm Des; 2015; 21(17):2259-75. PubMed ID: 25543123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highlighting the interplay of microRNAs from
    Rashidi S; Mansouri R; Ali-Hassanzadeh M; Ghani E; Barazesh A; Karimazar M; Nguewa P; Carrera Silva EA
    Parasitology; 2021 Oct; 148(12):1434-1446. PubMed ID: 34218829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposing of known drugs for leishmaniasis treatment using bioinformatic predictions, in vitro validations and pharmacokinetic simulations.
    Bustamante C; Ochoa R; Asela C; Muskus C
    J Comput Aided Mol Des; 2019 Sep; 33(9):845-854. PubMed ID: 31612362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.